Brevan Howard Capital Management LP Sells 22,824 Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Brevan Howard Capital Management LP decreased its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 28.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 56,644 shares of the biotechnology company’s stock after selling 22,824 shares during the period. Brevan Howard Capital Management LP’s holdings in BioCryst Pharmaceuticals were worth $426,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently made changes to their positions in BCRX. Vanguard Group Inc. increased its stake in BioCryst Pharmaceuticals by 7.8% in the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after acquiring an additional 1,583,826 shares during the last quarter. Caligan Partners LP increased its position in shares of BioCryst Pharmaceuticals by 16.0% during the 4th quarter. Caligan Partners LP now owns 2,995,932 shares of the biotechnology company’s stock valued at $22,529,000 after purchasing an additional 412,347 shares during the last quarter. Northern Trust Corp lifted its position in BioCryst Pharmaceuticals by 7.7% in the 4th quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company’s stock worth $15,077,000 after buying an additional 143,986 shares during the last quarter. Eversept Partners LP lifted its position in BioCryst Pharmaceuticals by 269.9% in the 4th quarter. Eversept Partners LP now owns 1,980,312 shares of the biotechnology company’s stock worth $14,892,000 after buying an additional 1,444,907 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in BioCryst Pharmaceuticals by 4.9% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock worth $14,890,000 after buying an additional 91,998 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Trading Up 0.6 %

Shares of NASDAQ BCRX opened at $9.98 on Friday. The firm has a fifty day simple moving average of $7.87 and a two-hundred day simple moving average of $7.89. The firm has a market capitalization of $2.09 billion, a PE ratio of -16.36 and a beta of 1.08. BioCryst Pharmaceuticals, Inc. has a 12 month low of $5.23 and a 12 month high of $11.11.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The business had revenue of $131.50 million for the quarter, compared to analyst estimates of $126.64 million. During the same period in the previous year, the business earned $0.28 EPS. BioCryst Pharmaceuticals’s revenue for the quarter was up 40.8% compared to the same quarter last year. On average, sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on BCRX shares. StockNews.com upgraded shares of BioCryst Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, April 29th. They set an “overweight” rating and a $20.00 price objective on the stock. Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a report on Monday, January 13th. JMP Securities reaffirmed a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Finally, Wedbush started coverage on BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. They set an “outperform” rating and a $15.00 price objective for the company. One analyst has rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus price target of $16.56.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.